30 Sep 2020 07:00
Total Voting Rights
Â
Â
London: Wednesday, September 30, 2020: Hutchison China MediTech Limited ("Chi-Med") (AIM/Nasdaq: HCM) hereby notifies the market that as at September 30, 2020, the issued share capital of Chi-Med consisted of 710,785,545 ordinary shares of US$0.10 each, with each share carrying one right to vote and with no shares held in treasury.
Â
The above figure of 710,785,545 may be used by shareholders as the denominator for the calculations by which they could determine if they are required to notify their interest in, or a change to their interest in, Chi-Med under the Financial Conduct Authority's Disclosure Rules and Transparency Rules.
Â
For illustrative purposes only, the 710,785,545 ordinary shares would be equivalent to 710,785,545 CREST depositary interests (each equating to one ordinary share) which are traded on AIM or, if the CREST depositary interests were converted in their entirety, equivalent to 142,157,109 American depositary shares (each equating to five ordinary shares) which are traded on Nasdaq.
Â
Â
About Chi-Med
Â
Chi-Med (Nasdaq/AIM: HCM) is an innovative, commercial-stage, biopharmaceutical company committed, over the past twenty years, to the discovery and global development of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. It has a portfolio of nine cancer drug candidates currently in clinical studies around the world and extensive commercial infrastructure in its home market of China. For more information, please visit: www.chi-med.com.
Â
Â
CONTACTS
Â
Investor Enquiries | |
Mark Lee, Senior Vice President | +852Â 2121Â 8200 |
Annie Cheng, Vice President | +1Â (973)Â 567Â 3786 |
Media Enquiries | Â |
Americas - Brad Miles, Solebury Trout | +1Â (917)Â 570Â 7340Â (Mobile)Â bmiles@troutgroup.com |
Europe - Ben Atwell / Alex Shaw, FTI Consulting | +44Â 20Â 3727Â 1030 / +44Â 7771Â 913Â 902Â (Mobile) / +44Â 7779Â 545Â 055Â (Mobile)Chi-Med@fticonsulting.com |
Asia - Joseph Chi Lo / Zhou Yi, Brunswick | +852Â 9850Â 5033 (Mobile), jlo@brunswickgroup.com / +852Â 9783Â 6894Â (Mobile), yzhou@brunswickgroup.com |
Nominated Advisor | |
Freddy Crossley / Atholl Tweedie, Panmure Gordon (UK)Â Limited | +44Â (20)Â 7886Â 2500 |
Â
Â